{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:13:20Z","timestamp":1789863200181,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,4,11]],"date-time":"2013-04-11T00:00:00Z","timestamp":1365638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,4,11]],"date-time":"2013-04-11T00:00:00Z","timestamp":1365638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s40259-013-0029-2","type":"journal-article","created":{"date-parts":[[2013,4,10]],"date-time":"2013-04-10T08:18:54Z","timestamp":1365581934000},"page":"263-274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Multicomponent Meningococcal Serogroup B Vaccine (4CMenB; Bexsero\u00ae): A Review of its Use in Primary and Booster Vaccination"],"prefix":"10.1007","volume":"27","author":[{"given":"Natalie J.","family":"Carter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,11]]},"reference":[{"key":"29_CR1","unstructured":"National Foundation for Infectious Diseases. The changing epidemiology of meningococcal disease among U.S. children, adolescents and young adults. 2004. http:\/\/www.nfid.org\/pdf\/meningitis\/FINALChanging_Epidemiology_of_Meningococcal_Disease.pdf. Accessed 11 Sep 2011."},{"issue":"4","key":"29_CR2","doi-asserted-by":"publisher","first-page":"B64","DOI":"10.1016\/j.vaccine.2009.04.061","volume":"27","author":"DA Caugant","year":"2009","unstructured":"Caugant DA, Maiden MCJ. Meningococcal carriage and disease: population biology and evolution. Vaccine. 2009;27(4):B64\u201370.","journal-title":"Vaccine"},{"key":"29_CR3","unstructured":"European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe. 2008\/09. http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/1107_SUR_IBD_2008-09.pdf. Accessed 4 Mar 2013."},{"issue":"18","key":"29_CR4","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","volume":"344","author":"NE Rosenstein","year":"2001","unstructured":"Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med. 2001;344(18):1378\u201388.","journal-title":"N Engl J Med"},{"issue":"9580","key":"29_CR5","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","volume":"369","author":"DS Stephens","year":"2007","unstructured":"Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580):2196\u2013210.","journal-title":"Lancet"},{"issue":"1","key":"29_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1574-6976.2006.00053.x","volume":"31","author":"CL Trotter","year":"2007","unstructured":"Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev. 2007;31(1):101\u20137.","journal-title":"FEMS Microbiol Rev"},{"key":"29_CR7","unstructured":"Novartis Vaccines. Meningococcal group C conjugate vaccine (Menjugate Kit\u00ae): UK prescribing information. 2012. http:\/\/www.medicines.org.uk\/EMC\/medicine\/16597\/SPC\/Menjugate+Kit\/. Accessed 4 Mar 2013."},{"key":"29_CR8","unstructured":"Pfizer Limited. Meningitec\u00ae in pre-filled syringe: UK prescribing information. 2011. http:\/\/www.medicines.org.uk\/EMC\/medicine\/20747\/SPC\/Meningitec+in+pre-filled+syringe\/. Accessed 4 Mar 2013."},{"key":"29_CR9","unstructured":"Novartis Vaccines and Diagnostics. Meningococcal group A, C, W135, and Y conjugate vaccine (Menveo\u00ae): EU prescribing information. 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001095\/WC500090147.pdf. Accessed 4 Mar 2013."},{"key":"29_CR10","unstructured":"EUVAC.net. Meningococcal vaccination (MenC) overview in European countries. http:\/\/www.euvac.net\/graphics\/euvac\/vaccination\/menc.html. Accessed 4 Mar 2013."},{"key":"29_CR11","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1099\/jmm.0.46288-0","volume":"55","author":"SJ Gray","year":"2006","unstructured":"Gray SJ, Trotter CL, Ramsay ME, et al. Epidemiology of meningococcal disease in England and Wales 1993\/94 to 2003\/04: contribution and experiences of the meningococcal reference unit. J Med Microbiol. 2006;55:887\u201396.","journal-title":"J Med Microbiol"},{"key":"29_CR12","doi-asserted-by":"crossref","unstructured":"Cohn AC, Harrison LH. Meningococcal vaccines: current issues and future strategies. Drugs 2013. In press.","DOI":"10.1007\/s40265-013-0079-2"},{"issue":"Suppl 2","key":"29_CR13","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1086\/648966","volume":"50","author":"DM Granoff","year":"2010","unstructured":"Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis. 2010;50(Suppl 2):S54\u201365.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"29_CR14","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1128\/JCM.00936-09","volume":"47","author":"J Lucidarme","year":"2009","unstructured":"Lucidarme J, Comanducci M, Findlow J, et al. Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J Clin Microbiol. 2009;47(11):3577\u201385.","journal-title":"J Clin Microbiol"},{"issue":"45","key":"29_CR15","doi-asserted-by":"publisher","first-page":"19490","DOI":"10.1073\/pnas.1013758107","volume":"107","author":"J Donnelly","year":"2010","unstructured":"Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA. 2010;107(45):19490\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5459","key":"29_CR16","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","volume":"287","author":"M Pizza","year":"2000","unstructured":"Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000;287(5459):1816\u201320.","journal-title":"Science"},{"issue":"4","key":"29_CR17","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","volume":"72","author":"LD Fletcher","year":"2004","unstructured":"Fletcher LD, Bernfield L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004;72(4):2088\u2013100.","journal-title":"Infect Immun"},{"key":"29_CR18","unstructured":"Novartis Vaccines and Diagnostics. Meningococcal group B vaccine (Bexsero\u00ae) suspension for injection: EU summary of product characteristics. 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002333\/WC500137881.pdf. Accessed 13 Feb 2013."},{"issue":"10","key":"29_CR19","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1086\/656741","volume":"51","author":"J Findlow","year":"2010","unstructured":"Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51(10):1127\u201337.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"29_CR20","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","volume":"29","author":"MD Snape","year":"2010","unstructured":"Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010;29(11):e71\u20139.","journal-title":"Pediatr Infect Dis J"},{"key":"29_CR21","doi-asserted-by":"publisher","unstructured":"Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomized trials. Lancet. 2013. doi:10.1016\/S0140-6736(12)61961-8.","DOI":"10.1016\/S0140-6736(12)61961-8"},{"issue":"6","key":"29_CR22","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jama.2012.85","volume":"307","author":"N Gossger","year":"2012","unstructured":"Gossger N, Snape MD, Yu L-M, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307(6):573\u201382.","journal-title":"JAMA"},{"issue":"9816","key":"29_CR23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","volume":"379","author":"ME Santolaya","year":"2012","unstructured":"Santolaya ME, O\u2019Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379(9816):617\u201324.","journal-title":"Lancet"},{"issue":"3","key":"29_CR24","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1128\/CVI.00304-10","volume":"18","author":"A Kimura","year":"2011","unstructured":"Kimura A, Toneatto D, Kleinschmidt A, et al. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol. 2011;18(3):483\u20136.","journal-title":"Clin Vaccine Immunol"},{"key":"29_CR25","unstructured":"Prymula R, Vesikari T, Esposito S, et al. Catch-up vaccination of healthy toddlers with an investigational multicomponent meningococcal serogroup B vaccine (4CMenB):exploration of a two-dose schedule [poster]. 29th European Society for Paediatric Infectious Diseases Conference; 7\u201311 June 2011; The Hague."},{"key":"29_CR26","unstructured":"Vesikari T, Prymula R, Liese J, et al. Booster dose at 12 months of an investigational meningococcal serogroup B vaccine (4CMenB) in healthy toddlers previously primed at 2, 4, 6 months [poster]. 29th European Society for Paediatric Infectious Diseases Conference; 7\u201311 June 2011; The Hague."},{"key":"29_CR27","doi-asserted-by":"publisher","unstructured":"Vogel U, Taha M-K, Vazquez JA, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013. doi:10.1016\/S1473-3099(13)70006-9.","DOI":"10.1016\/S1473-3099(13)70006-9"},{"key":"29_CR28","unstructured":"Beeretz I, MD S, A F, et al. Reactogenicity and safety of multicomponent meningococcal serogroup B vaccine (4CMenB) administered with or without routine infant vaccinations in different schedules [poster]. 29th European Society for Paediatric Infectious Diseases Conference; 7\u201311 June 2011; The Hague."},{"key":"29_CR29","unstructured":"Novartis. Novartis candidate vaccine Bexsero\u00ae shows significant potential in providing broad coverage against meningococcal serogroup B infections. 2011. http:\/\/www.novartis.com\/newsroom\/media-releases\/en\/2011\/1522283.shtml. Accessed 28 Mar 2013."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-013-0029-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-013-0029-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-013-0029-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-013-0029-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:05:10Z","timestamp":1744715110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-013-0029-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,11]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["29"],"URL":"https:\/\/doi.org\/10.1007\/s40259-013-0029-2","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,11]]},"assertion":[{"value":"11 April 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}